Every 8-K that Modular Medical, Inc. (MODD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MODD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MODD filings page.
Modular Medical, Inc. (MODD) announced that its fiscal 2027 Annual Meeting of Shareholders will be held as a virtual meeting on October 23, 2026. Shareholders of record at the close of business on September 10, 2026 will be entitled to receive notice of and vote at the meeting.
Shareholder proposals and director nominations for the 2027 Annual Meeting must be received by the Company’s Secretary at its San Diego principal executive offices by 5:00 p.m. (Eastern time) on September 13, 2026, whether for inclusion in proxy materials under Rule 14a-8 or brought outside Rule 14a-8 under the Company’s bylaws. Shareholders intending to use the universal proxy rules for their own director nominees must also provide the Rule 14a-19 notice by this same deadline.
Modular Medical, Inc. disclosed new stock option awards for two senior executives. On May 14, 2026, the board granted 11,218 stock options to Chairman, President, Chief Financial Officer and Treasurer Paul DiPerna and 4,674 stock options to Chief Operating Officer Kevin Schmid.
The options carry an exercise price of $3.46 per share, vest with one-third of the shares on May 14, 2027 and the remaining shares vesting monthly over the following 24 months, contingent on continued service. The options expire on May 14, 2036 and were issued under the company’s Amended and Restated 2017 Equity Incentive Plan.
Modular Medical, Inc. entered into a Placement Agency Agreement for a registered direct offering of 750,000 shares of common stock at $4.50 per share, for expected gross proceeds of about $3.375 million before fees and expenses.
Maxim Group LLC will act as sole placement agent, earning a 7% cash fee on gross proceeds and expense reimbursement up to $75,000. The offering is made under an effective Form S-3 shelf registration and is expected to close on or about April 21, 2026, subject to customary conditions.
Company directors and executive officers agreed to 90-day lock-up restrictions, and the Company agreed to limit additional equity issuances for 45 days after closing, subject to specified exceptions.
Modular Medical, Inc. has regained compliance with the Nasdaq Capital Market’s minimum bid price continued listing requirement. Nasdaq notified the company after its common stock maintained a closing bid above the $1.00 minimum for 10 consecutive trading days through April 14, 2026.
With compliance restored under Nasdaq Listing Rule 5550(a)(2), Nasdaq considers the matter closed, meaning the company’s common stock can continue trading on the Nasdaq Capital Market under the symbol MODD without an active bid-price deficiency issue.
Modular Medical, Inc. is implementing a 1-for-30 reverse stock split of its common stock. The change became effective at 5:30 a.m. Eastern Time on March 31, 2026, and the shares now trade on a split-adjusted basis on Nasdaq under the same symbol, MODD, with new CUSIP 60785L306.
The reverse split reduces outstanding common shares from 139,810,797 to approximately 4,660,360, while leaving the number of authorized shares and the $0.001 par value unchanged. It was approved by shareholders and the board and is intended to raise the per-share price to meet Nasdaq’s $1.00 minimum bid price requirement.
Every 30 pre-split shares are combined into one post-split share, with proportional voting and other rights maintained. Equity awards, plan reserves, and warrants are adjusted accordingly, and holders of fractional shares receive cash instead of partial shares. The company’s transfer agent will manage the exchange process for shareholders.
Modular Medical, Inc. reported a major workforce reduction to cut costs and extend its cash resources. On March 12, 2026 the company laid off 20 employees, representing approximately 29% of its workforce. Management expects this move to lower annual operating expenses by about $3.4 million, helping align spending with projects viewed as having higher return on investment. The company anticipates one-time severance and related charges of roughly $0.1 million to $0.2 million, with most of these costs incurred by the quarter ending June 30, 2026. Actual charges and savings may differ materially from these estimates.
Modular Medical, Inc. completed a best-efforts public offering of 68,098,000 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants, generating approximately $12 million in gross proceeds before fees and expenses.
The deal included 62,098,000 shares of common stock, 6,000,000 pre-funded warrants, and common warrants to purchase up to 68,098,000 shares, all priced at a combined $0.1762 per share (or pre-funded warrant) and warrant. The common warrants are immediately exercisable at $0.1762 per share and expire five years after issuance, with ownership capped at 4.99% or, at the holder’s election, 9.99% of outstanding common stock after exercise.
Directors and executive officers agreed to 90‑day lock-ups, and the company agreed to limits on variable rate issuances for 45 days after closing. Maxim Group LLC acted as placement agent, receiving a 7% cash fee on gross proceeds plus $100,000 in expense reimbursement.
Modular Medical, Inc. entered into a new secured promissory note with its chief executive officer, James E. Besser, creating a $350,000 revolving credit facility. The note carries 12% interest on each draw and matures on March 25, 2026, with all company assets and intellectual property pledged as collateral.
The company has not yet borrowed under this facility. Principal and interest must be repaid by the maturity date or earlier if the company raises more than $2,000,000 in equity financings before maturity. Individual draw requests must be at least $50,000 and cannot exceed the remaining availability under the credit limit.
Modular Medical, Inc. reported that shareholders approved a charter amendment increasing the company’s authorized common stock from 100,000,000 to 250,000,000 shares. This amendment was filed with the Nevada secretary of state on January 23, 2026, and reflects shareholder approval at the 2026 annual meeting.
At the annual meeting, a quorum representing approximately 69% of the outstanding common shares entitled to vote was present in person, virtually, or by proxy. All nominated directors, including Duane DeSisto, Paul DiPerna, and other candidates listed, were elected to serve until the next annual meeting. The filing also shows that shareholders approved each of the six proposals presented, based on the reported vote totals.
Modular Medical, Inc. entered into an underwriting agreement for a firm commitment public offering of 12,173,000 shares of common stock, together with accompanying warrants exercisable for up to 6,086,500 shares. The transaction is expected to generate approximately $4.68 million in gross proceeds before underwriting discounts, commissions and expenses.
Each two shares of common stock are sold with one warrant at a combined price of $0.77, with the warrants exercisable immediately at $0.45 per share for five years. The company agreed to pay the underwriter a 7% cash fee plus up to $85,000 of expenses, granted a 30‑day over‑allotment option for additional shares and warrants, and issued underwriter warrants equal to 7% of the firm shares. Directors and executive officers are subject to 60‑day lock‑ups, and the company agreed to a 90‑day lock‑up on additional equity sales.
Modular Medical, Inc. entered into inducement agreements with certain holders of existing warrants, prompting them to exercise a portion of their warrants at a reduced cash exercise price of $0.68 per share, compared with the $0.7611 Nasdaq Official Closing Price on September 19, 2025. Holders agreed to exercise 2023 warrants covering 1,519,200 shares and 2025 warrants covering 3,975,428 shares, and the company expects to receive approximately $3.7 million in gross proceeds before related expenses.
In return, Modular Medical will issue new warrants to purchase approximately 2,747,314 shares of common stock, with an exercise price of $0.84 per share and a five-year term starting on the issuance date. These new warrants will be unlisted, carry Securities Act restrictive legends, and may be exercised on a cashless basis under certain conditions. The transaction is expected to close on or about September 25, 2025, and the company plans to use commercially reasonable efforts to register the resale of the shares underlying the new warrants.